Atossa Therapeutics, Inc.

NasdaqCM:ATOS Voorraadrapport

Marktkapitalisatie: US$188.6m

Atossa Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Atossa Therapeutics is Steve Quay, benoemd in Apr2009, heeft een ambtstermijn van 15.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.36M, bestaande uit 30% salaris en 70% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.002% van de aandelen van het bedrijf, ter waarde $ 3.98K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 12.8 jaar.

Belangrijke informatie

Steve Quay

Algemeen directeur

US$2.4m

Totale compensatie

Percentage CEO-salaris30.0%
Dienstverband CEO15.6yrs
Eigendom CEO0.002%
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur12.8yrs

Recente managementupdates

Recent updates

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Nov 08

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Jul 01
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Apr 26
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Jan 09
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Oct 11

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Sep 25
We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics GAAP EPS of -$0.05

Aug 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

A First Assessment On Atossa Therapeutics

Dec 10

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 02
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Sep 22

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Jul 17
Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Atossa Therapeutics: Hope Springs Eternal

Jun 30

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Jun 16

Atossa reaches a two-year high ahead of data readout for breast cancer therapy

Jun 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Apr 02
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa updates on single-patient study for Endoxifen

Feb 04

Atossa halts Endoxifen breast cancer study after positive data

Feb 02

Atossa Therapeutics prices ~$25M direct offering, stock -23% PM

Jan 06

Atossa Therapeutics prices $14M registered direct offering

Dec 17

We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 10
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics plummets 38% after it raises $20M in public offering

Dec 09

Atossa Therapeutics EPS in-line

Nov 13

Safety data on COVID-19 nasal spray fails to lift Atossa, down 6%

Nov 10

Analyse CEO-vergoeding

Hoe is Steve Quay's beloning veranderd ten opzichte van Atossa Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$2mUS$706k

-US$30m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$3mUS$706k

-US$27m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$6mUS$659k

-US$21m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$3mUS$601k

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$13m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$6mUS$601k

-US$17m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$25m

Dec 31 2018US$2mUS$582k

-US$23m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$22m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$1mUS$520k

-US$11m

Compensatie versus markt: De totale vergoeding ($USD 2.36M ) Steve } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.47M ).

Compensatie versus inkomsten: De vergoeding van Steve is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Steve Quay (73 yo)

15.6yrs

Tenure

US$2,356,220

Compensatie

Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Steven Quay
Chairman15.6yrsUS$2.36m0.0021%
$ 4.0k
Heather Rees
Chief Financial Officer & Principal Accounting Officer3.8yrsUS$687.46k0%
$ 0
Delly Behen
Senior Vice President of Administration & HR10.3yrsgeen gegevensgeen gegevens
Eric Van Zanten
Vice President of Investor & Public Relations2.8yrsgeen gegevensgeen gegevens
Richard Graydon
Interim Chief Medical Officer2.1yrsgeen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van ATOS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Steven Quay
Chairman15.6yrsUS$2.36m0.0021%
$ 4.0k
Richard Steinhart
Independent Director10.7yrsUS$146.17k0%
$ 0
H. Remmel
Independent Director12.8yrsUS$144.92k0.00020%
$ 377.3
Shu-Chih Chen
Director15.6yrsUS$116.17k0.018%
$ 33.4k
Stephen Galli
Independent Director13.3yrsUS$144.92k0.000080%
$ 150.9
Jonathan Finn
Independent Directorless than a yearUS$93.98k0.020%
$ 37.5k
Tessa Cigler
Independent Directorless than a yeargeen gegevensgeen gegevens

12.8yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ATOS zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.8 jaar).